These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Long-term follow-up of allogeneic hematopoietic stem cell transplantation for de novo acute myelogenous leukemia with a conditioning regimen of total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine. Mori T; Aisa Y; Watanabe R; Yamazaki R; Kato J; Shimizu T; Shigematsu N; Kubo A; Yajima T; Hibi T; Ikeda Y; Okamoto S Biol Blood Marrow Transplant; 2008 Jun; 14(6):651-7. PubMed ID: 18489990 [TBL] [Abstract][Full Text] [Related]
3. High-dose therapy with autologous or allogeneic transplantation as salvage therapy for small cleaved cell lymphoma of follicular center cell origin. Stein RS; Greer JP; Goodman S; Kallianpur A; Ahmed MS; Wolff SN Bone Marrow Transplant; 1999 Feb; 23(3):227-33. PubMed ID: 10084253 [TBL] [Abstract][Full Text] [Related]
5. Autologous transplantation in patients with relapsed or high-grade follicular lymphoma provides long term disease-free survival and best median duration of response. Ganguly S; Divine CL; Deauna-Limayo D; Bodensteiner DC; Cook JD; Lewis JN; Skikne BS Ann Hematol; 2005 Aug; 84(8):526-31. PubMed ID: 15915350 [TBL] [Abstract][Full Text] [Related]
9. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia. Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR; Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337 [TBL] [Abstract][Full Text] [Related]
10. High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma. Law LY; Horning SJ; Wong RM; Johnston LJ; Laport GG; Lowsky R; Shizuru JA; Blume KG; Negrin RS; Stockerl-Goldstein KE Biol Blood Marrow Transplant; 2006 Jul; 12(7):703-11. PubMed ID: 16785059 [TBL] [Abstract][Full Text] [Related]
11. Excellent outcome of allogeneic hematopoietic stem cell transplantation using a conditioning regimen with medium-dose VP-16, cyclophosphamide and total-body irradiation for adult patients with acute lymphoblastic leukemia. Shigematsu A; Kondo T; Yamamoto S; Sugita J; Onozawa M; Kahata K; Endo T; Shiratori S; Ota S; Obara M; Wakasa K; Takahata M; Takeda Y; Tanaka J; Hashino S; Nishio M; Koike T; Asaka M; Imamura M Biol Blood Marrow Transplant; 2008 May; 14(5):568-75. PubMed ID: 18410899 [TBL] [Abstract][Full Text] [Related]
12. High complete response rate after allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning regimens in advanced malignant lymphoma. Tanimoto TE; Kusumi E; Hamaki T; Yuji K; Ueyama J; Miyakoshi S; Morinaga S; Kami M; Kanda Y; Ando T; Yoshihara S; Masuo S; Kim SW; Nakai K; Tobinai K; Tanosaki R; Mineishi S; Takaue Y; Muto Y Bone Marrow Transplant; 2003 Jul; 32(2):131-7. PubMed ID: 12838276 [TBL] [Abstract][Full Text] [Related]
13. [Allogeneic transplantation in malignant lymphoma]. Stötzer OJ; Schleuning M; Ledderose G; Hiddemann W; Kolb HJ Dtsch Med Wochenschr; 2001 Sep; 126(39):1062-9. PubMed ID: 11602913 [TBL] [Abstract][Full Text] [Related]
14. Long-term follow-up of reduced-intensity allogeneic hematopoietic stem cell transplantation for refractory or relapsed follicular lymphoma. Ono Y; Mori T; Kato J; Yamane A; Shimizu T; Kikuchi T; Kohashi S; Okamoto S Am J Hematol; 2012 Sep; 87(9):929-31. PubMed ID: 22674621 [TBL] [Abstract][Full Text] [Related]
15. Lowered-intensity preparative regimen for allogeneic stem cell transplantation delays acute graft-versus-host disease but does not improve outcome for advanced hematologic malignancy. Levine JE; Uberti JP; Ayash L; Reynolds C; Ferrara JL; Silver SM; Braun T; Yanik G; Hutchinson R; Ratanatharathorn V Biol Blood Marrow Transplant; 2003 Mar; 9(3):189-97. PubMed ID: 12652470 [TBL] [Abstract][Full Text] [Related]
16. [Effects and prognostic factors of HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia]. Tong XZ; Li J; Tan EX; Zhang GC; Wu XY; Peng AH; Zheng D; Zou WY; Hong WD; Luo SK Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):545-8. PubMed ID: 17147125 [TBL] [Abstract][Full Text] [Related]
17. Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies. Valcárcel D; Martino R; Sureda A; Canals C; Altés A; Briones J; Sanz MA; Parody R; Constans M; Villela SL; Brunet S; Sierra J Eur J Haematol; 2005 Feb; 74(2):144-51. PubMed ID: 15654906 [TBL] [Abstract][Full Text] [Related]
18. Establishment of early donor engraftment after reduced-intensity allogeneic hematopoietic stem cell transplantation to potentiate the graft-versus-lymphoma effect against refractory lymphomas. Bishop MR; Hou JW; Wilson WH; Steinberg SM; Odom J; Castro K; Kasten-Sportes C; Gea-Banacloche J; Marchigiani D; Gress R; Fowler DH Biol Blood Marrow Transplant; 2003 Mar; 9(3):162-9. PubMed ID: 12652466 [TBL] [Abstract][Full Text] [Related]
19. Low transplant-related mortality after second allogeneic peripheral blood stem cell transplant with reduced-intensity conditioning in adult patients who have failed a prior autologous transplant. Martino R; Caballero MD; de la Serna J; Díez-Martín JL; Urbano-Ispízua A; Tomás JF; Odriozola J; León A; Canals C; San Miguel J; Sierra J Bone Marrow Transplant; 2002 Jul; 30(2):63-8. PubMed ID: 12132043 [TBL] [Abstract][Full Text] [Related]
20. Long-term follow-up of allogeneic stem cell transplantation in patients with severe aplastic anemia after conditioning with cyclophosphamide plus antithymocyte globulin. Kröger N; Zabelina T; Renges H; Krüger W; Kordes U; Rischewski J; Schrum J; Horstmann M; Ayuk F; Erttmann R; Kabisch H; Zander AR Ann Hematol; 2002 Nov; 81(11):627-31. PubMed ID: 12454700 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]